Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 40, 2023 - Issue 4
Submit an article Journal homepage
160
Views
1
CrossRef citations to date
0
Altmetric
Brief Reports

Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma

Brandon Lucaria Department of Pediatrics at Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5428-5863
ORCID Icon,
Eran Tallisb Department of Molecular and Human Genetics at Baylor College of Medicine, Houston, Texas, USAORCID Iconhttps://orcid.org/0000-0002-7492-1844
ORCID Icon,
Vernon Reid Suttonc Department of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USAORCID Iconhttps://orcid.org/0000-0002-6450-8554
ORCID Icon &
Timothy Poread Department of Pediatrics Division of Hematology Oncology, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USAORCID Iconhttps://orcid.org/0000-0002-8071-6142
ORCID Icon
Pages 422-428 | Received 03 May 2022, Accepted 29 Aug 2022, Published online: 20 Sep 2022

References

  • Charrow J. Enzyme replacement therapy for Gaucher disease. Expert Opin Biol Ther. 2009;9(1):121–131. doi:10.1517/14712590802573395.
  • Weinreb NJ, Andersson HC, Banikazemi M, et al. Prevalence of type 1 Gaucher disease in the united states. Arch Intern Med. 2008;168(3):326–327. doi:10.1001/archinternmed.2007.128.
  • Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher registry. Blood. 2005;105(12):4569–4572. doi:10.1182/blood-2004-12-4672.
  • Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009;84(4):208–214. doi:10.1002/ajh.21362.
  • Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324(21):1464–1470. doi:10.1056/NEJM199105233242104.
  • Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer. 1993;72(1):219–224. doi:10.1002/1097-0142(19930701)72:13.0.co;2-y.
  • de Fost M, Vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006;36(1):53–58. doi:10.1016/j.bcmd.2005.08.004.
  • Murugesan V, Lischuk A, Haims A, et al. Case series and literature review of skeletal tumors and their incidence in the Gaucher disease population. Am J Hematol. 2016;91(7):736–741. doi:10.1002/ajh.24398.
  • Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the children’s oncology group. J Clin Oncol. 2012;30(33):4148–4154. doi:10.1200/JCO.2011.41.5703.
  • Merjaneh N, Young J, Mangoli A, et al. Chemotherapy-induced thrombocytopenia in Ewing sarcoma: implications and potential for romiplostim supportive care. Pediatric Blood & Cancer. 2022;69(7):e29548. doi:10.1002/pbc.29548.
  • Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog. 2013;18(3):235–246. doi:10.1615/critrevoncog.2013006145.
  • Lo SM, Choi M, Liu J, et al. Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis. Blood. 2012;119(20):4731–4740. doi:10.1182/blood-2011-10-386862.
  • Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–2346. doi:10.1056/NEJMoa1508054.
  • Manz M, Riessen R, Poll L, et al. High-grade lymphoma mimicking bone crisis in Gaucher’s disease. Br J Haematol. 2001;113(1):191–193. doi:10.1046/j.1365-2141.2001.02725.x.
  • Brody JD, Advani R, Shin LK, Bingham DB, Rosenberg SA. Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: diagnostic and therapeutic challenges. Ann Hematol. 2006;85(11):817–820. doi:10.1007/s00277-006-0176-3.
  • Leone JP, Dudek AZ. Enzyme replacement therapy for Gaucher’s disease in patient treated for non-small cell lung cancer. Anticancer Res. 2008;28(6B):3937–3939.
  • Ha CI, DeArmey S, Cope H, Rairikar M, Kishnani PS. Treatment of profound thrombocytopenia in a patient with Gaucher disease type 1: is there a role for substrate reduction therapy. Mol Genet Metab Rep. 2017;12:82–84. doi:10.1016/j.ymgmr.2017.06.003.
  • Lee N, Chien Y, Wang C, et al. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3. Mol Genet Metab Rep. 2022;31:100867. doi:10.1016/j.ymgmr.2022.100867.
  • Amato D, Patterson MA. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports. J Med Case Rep. 2018;12(1):19. doi:10.1186/s13256-017-1541-7.
  • Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;110(7):2296–2301. doi:10.1182/blood-2007-02-075960.
  • Guidance for industry and review staff on labeling for human prescription drug and biological products–determining established pharmacologic class for use in the highlights of prescribing information; availability. The Federal Register/FIND. 2009;74(200):53507.
  • Beutler E. Enzyme replacement in Gaucher disease. PLoS Med. 2004;1(2):e21. doi:10.1371/journal.pmed.0010021.
  • Zhang X, Chuai Y, Nie W, Wang A, Dai G, Dai G. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev. 2017;2017(11):CD012035. doi:10.1002/14651858.CD012035.pub2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.